CCCC
C4 Therapeutics Inc

2,257
Loading...
Loading...
News
all
press releases
C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Misses Revenue Estimates
C4 Therapeutics (CCCC) delivered earnings and revenue surprises of +2.63% and -0.57%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
More News
News Placeholder
Ocugen (OCGN) Reports Q2 Loss, Misses Revenue Estimates
Ocugen (OCGN) delivered earnings and revenue surprises of +16.67% and -1.93%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Tops Revenue Estimates
chainwire·4mo ago
News Placeholder
PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ('PureTech' or the 'Company'), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, (Seaport) a...
Business Wire·10mo ago
News Placeholder
Analysts Offer Insights on Healthcare Companies: Liquidia Technologies (LQDA), C4 Therapeutics (CCCC) and Lineage Therap (LCTX)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Liquidia Technologies (LQDA Research Report), C4 Therapeutics...
TipRanks Financial Blog·1y ago
News Placeholder
Biotech Sector Working to Combat Rising Cases of Colorectal Cancer in Young Adults
Biotech Sector Working to Combat Rising Cases of Colorectal Cancer in Young Adults Biotech Sector Working to Combat Rising Cases of Colorectal Cancer in Young Adults PR Newswire VANCOUVER, BC, May...
PR Newswire·1y ago
News Placeholder
Key Takeaways From C4 Therapeutics Analyst Ratings
Latest Ratings for CCCC DateFirmActionFromTo Mar 2022JP MorganInitiates Coverage OnOverweight Feb 2022Wells FargoInitiates Coverage OnEqual-Weight Nov 2021B of A SecuritiesInitiates Coverage OnBuy...
Benzinga·1y ago
News Placeholder
C4 Therapeutics, Inc. (NASDAQ:CCCC) Sees Significant Increase in Short Interest
C4 Therapeutics, Inc. (NASDAQ:CCCC Get Free Report) saw a significant growth in short interest in March. As of March 15th, there was short interest totalling 5,290,000 shares, a growth of...
Ticker Report·1y ago
News Placeholder
C4 Therapeutics (NASDAQ:CCCC) Trading Down 3.9%
Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC Get Free Report) dropped 3.9% during mid-day trading on Wednesday . The company traded as low as $8.35 and last traded at $8.35. Approximately...
Ticker Report·1y ago
News Placeholder
C4 Therapeutics (NASDAQ:CCCC) Shares Down 6.8%
C4 Therapeutics, Inc. (NASDAQ:CCCC Get Free Report) shares dropped 6.8% during trading on Thursday . The company traded as low as $9.92 and last traded at $10.00. Approximately 560,028 shares...
Ticker Report·1y ago

Latest CCCC News

View

Advertisement. Remove ads.

Advertisement. Remove ads.